GSK wins FDA approval for hepatitis B drug that extends functional cures

The Food and Drug Administration has approved a hepatitis B drug developed by GSK, according to STAT News, which reported the drug extended functional cures to far more patients than previous treatment methods achieved.

The approval marks a therapeutic advance for a chronic viral infection that has long resisted elimination in most patients under existing standards of care. STAT News reported the GSK drug’s performance in extending functional cures represents a meaningful departure from prior treatment outcomes, though the publication’s full account of trial data and mechanism sits behind its subscriber paywall.

Hepatitis B remains a chronic condition for hundreds of millions of people worldwide, with current antiviral regimens typically suppressing the virus without eliminating it. A functional cure, in which the virus is controlled to the point that treatment can stop without relapse, has been a stated goal of hepatitis B drug development for years, pursued by multiple pharmaceutical companies and research groups.

STAT News did not specify in the material reviewed here the exact patient population, dosing regimen, or comparative trial design underlying the approval. The publication’s report was dated October 21, 2026.

The approval adds GSK to the roster of companies with FDA-cleared hepatitis B therapies, though further reporting beyond STAT’s initial account will be needed to establish the drug’s place relative to competing treatments in development.